Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): A phase 2B, open-label, randomised controlled trial
- Park, K.
- Tan, E.-H.
- O'Byrne, K.
- Zhang, L.
- Boyer, M.
- Mok, T.
- Hirsh, V.
- Yang, J.C.-H.
- Lee, K.H.
- Lu, S.
- Shi, Y.
- Kim, S.-W.
- Laskin, J.
- Kim, D.-W.
- Arvis, C.D.
- Kölbeck, K.
- Laurie, S.A.
- Tsai, C.-M.
- Shahidi, M.
- Kim, M.
- Massey, D.
- Zazulina, V.
- Paz-Ares, L.
ISSN: 1474-5488, 1470-2045
Datum der Publikation: 2016
Ausgabe: 17
Nummer: 5
Seiten: 577-589
Art: Artikel